New York, Feb 27, 2026, 08:31 EST — Premarket.
- LMAT was flat premarket after jumping 24.4% on Thursday to close at $113.69
- LeMaitre posted Q4 sales of $64.5 million and guided 2026 sales to about $280 million at the midpoint
- Citizens lifted its price target to $118, citing EPS guidance above consensus
LeMaitre Vascular shares were little changed in premarket trading on Friday after the vascular device maker surged 24.4% in the prior session. The stock closed at $113.69 on Thursday after trading as high as $115.33, with volume at about 1.27 million shares versus roughly 203,000 the day before. 1
The jump matters because it resets expectations for a company that typically trades on small shifts in growth and margins. After Thursday’s pop, investors will spend Friday figuring out whether the new outlook is “real enough” to keep the stock pinned at a higher level.
LeMaitre late Wednesday reported fourth-quarter sales of $64.5 million, up 16% from a year earlier, including 15% “organic” growth, a measure that strips out currency swings and other items. Diluted earnings per share rose 39% to $0.68, and gross margin climbed 240 basis points — or 2.4 percentage points — to 71.7%, it said. It forecast full-year 2026 sales of $276 million to $284 million and EPS of $2.81 to $3.01, while CEO George LeMaitre cited “international Artegraft growth” and higher average selling prices as the quarter’s main levers. 2
Citizens analyst Daniel Stauder raised his price target on the shares to $118 from $113 and kept a Market Outperform rating, an Investing.com report showed. He said the company’s midpoint adjusted EPS guidance of about $2.91 was roughly 13% above consensus estimates near $2.58. 3
The next thing traders will watch is simple: does the stock hold above the old range once the regular session opens, or does it sag under the weight of a one-day re-rate. Estimate revisions over the next few days matter too, because Thursday’s move was built on forward numbers.
But the outlook is not frictionless. On its earnings call, LeMaitre said it dealt with a January cyber incident and that its review is still ongoing, even as it said it restored critical systems with “minimal to no disruption.” Management also warned that a manufacturing transfer tied to its RestoreFlow processing and the opening of a new 34,000-square-foot warehouse could pressure margins later in the year, with 2026 capital spending expected to rise to about $11 million. 4
A rally like Thursday’s also leaves less room for bad luck — on costs, on pricing, or on procedure volumes. If the margin story stalls, the stock can give back ground fast, and it tends to do it in a hurry.
Investors also have a near-term calendar to track: the board raised the quarterly dividend 25% to $0.25 a share, payable on March 26 to shareholders of record on March 12, and approved a share repurchase program of up to $100 million that runs through Feb. 18, 2027. Those dates — and the pace of buybacks — are likely to be the next hard catalyst after Friday’s open. 5
